Amoxicillin and Clavulanate Oral Suspension For Child

Amoxicillin and Clavulanate Potassium for oral suspension is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta-lactamase inhibitor, indicated for the treatment of pediatric patients with:

• Recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs less than 2 mcg/mL), H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors

– Antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) daycare attendance.

​Limitations of Use

Acute otitis media due to S. pneumoniae alone can be treated with amoxicillin. Amoxicillin and Clavulanate Potassium for oral suspension is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC greater than or equal to 4 mcg/mL. Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC less than or equal to 2 mcg/mL) and the β-lactamase-producing organisms listed above.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium for oral suspension and other antibacterial drugs, Amoxicillin and Clavulanate Potassiumfor oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1)

• Pediatric Patients less than 40 kg: 90 mg/kg/day divided every 12 hours, administered for 10 days.

• History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium for oral suspension or any other beta-lactams (e.g., penicillins or cephalosporins).
• History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium for oral suspension.

• Serious (including fatal) hypersensitivity reactions: Discontinue Amoxicillin and Clavulanate Potassium for oral suspension if a reaction occurs.
• Severe Cutaneous Adverse Reactions (SCAR): Monitor closely. Discontinue if rash progresses.
• Hepatic dysfunction and cholestatic jaundice: Discontinue if signs/symptoms of hepatitis occur. Monitor liver function tests in patients with hepatic impairment
• Clostridioides difficile-associated diarrhea (CDAD) (ranging from mild diarrhea to fatal colitis): Evaluate patients if diarrhea occurs.
• Patients with mononucleosis who receive Amoxicillin and Clavulanate Potassium for oral suspension develop skin rash. Avoid use of the drug in these patients.

The most frequently reported adverse reactions were diaper rash (4%), diarrhea (3%), vomiting (2%), candidiasis (1%), and rash (1%).

• Co-administration with probenecid is not recommended.
• Concomitant use of Amoxicillin and Clavulanate Potassium for oral suspension with oral anticoagulants may increase the prolongation of prothrombin time.
• Co-administration with allopurinol increases the risk of rash.
• Amoxicillin and Clavulanate Potassium for oral suspension may reduce efficacy of oral contraceptives. (7.4)

• Pediatric 3 months to 12 years old: Modify dose according to weight.
• Adults and pediatric patients weighing more than 40 kg: The safety and effectiveness of Amoxicillin and Clavulanate Potassium for oral suspension has not been established.